Greg Kunst

Greg Kunst is the Founder, Chief Executive Officer, and Board Director of Aurion Biotech, a company specializing in cell therapies for serious eye disorders, recognized as the 2022 Prix Galien Top Biotech/Pharma Start-up and winner of multiple 2023 awards. Kunst also serves as a Board Director at Pr3vent INC, dedicated to newborn eye health, and as a Strategic Advisor at OCULOGICA. Previous roles include Vice President of Global Marketing and Market Access at Glaukos Corporation and various marketing and reimbursement positions at Alcon, Acelity, and CooperVision. Greg Kunst holds a B.S. in Economics from Brigham Young University and an MBA from Vanderbilt University, along with additional strategic leadership training from The Tuck School of Business at Dartmouth and Novartis.